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Sir,
Daptomycin is a new lipopeptide antibiotic with potent
activity against Methicillin-resistant Staphylococcus aur-
eus. It is a bactericidal agent that has the potential to
treat infections caused by multi-drug-resistant gram-
positive organisms. Although the mainstay of treatment is
based on glycopeptides, treatment with vancomycin is
frequently reported as often unsuccessful [1–3]. We
describe a case of Methicillin-resistant Staphylococcus
aureus (MRSA) diskitis successfully treated with intra-
venous daptomycin. A 38-year-old man was admitted to
our department for lumbar pain and fever. Other surgeons
have submitted the patient to surgery for L5-S1 discec-
tomy and they discharged him with empirical treatment
of ceftriaxone (2 g/day). At admission to our department,
he had no notable examination ﬁndings, except for fever
of 39.2C. CT revealed typical ﬁndings of diskitis
(Fig. 1a) and MRSA was isolated from blood cultures.
We did not perform surgical operation and preferred
conservative treatment. Because of the patient’s history
of vancomycin allergy, daptomycin treatment was
initiated (6 mg/kg every 24 h i.v.) and treatment with
other antibiotics was discontinued. Erythrocyte sedimen-
tation rates and serum C-reactive protein levels returned
to the preoperative levels, within 15 days after the initi-
ation of the treatment. Additional blood cultures showed
no growth after antibiotic therapy was initiated, and
daptomycin was tolerated by patient without treatment-
related adverse events. Results of follow-up cultures
showed bacterial eradication, nevertheless, we decided to
stop the therapy, when MR and scintigraphy with labeled
leucocytes were normal to avoid the return of the
infection and we needed to continue the daptomycin
therapy for 92 days; he returned to his work, without any
residual neurologic deﬁcits (Fig. 1b, c). The usual ther-
apeutic choice in cases of MRSA infections is a glyco-
peptide with or without rifampin, but increasing evidence
indicates decreasing effectiveness of vancomycin for
Staphylococcus aureus infection. [1–3]. For patients who
develop a reaction to vancomycin, treatment of MRSA
infections remains clinically challenging. Daptomycin has
potent bactericidal activity against gram-positive bacteria,
i.e., concentration-dependent. Unlike agents that are
active against the cell wall, daptomycin causes rapid
bactericidal activity without cell lysis, which could
reduce the release of bacterial molecules and lessen the
inﬂammatory response [1–3]. The US Food and Drug
Administration has approved daptomycin for the treat-
ment of complicated skin and skin structure infections
caused by susceptible pathogens as well as for bactere-
mia, including right-sided endocarditis, caused by MRSA
[1–4]. Other authors have reported cases of severe
myopathy and acute renal failure related to daptomycin
[4, 5]. Our case suggests that daptomycin is a safe and
effective option for the treatment of MRSA diskitis,
without treatment-related adverse events.
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Fig. 1 a CT showing typical
ﬁndings of discitis after left
interlaminar approach for L5-S1
discectomy. b MR showing no
inﬂammatory ﬁndings, after
daptomycin therapy.
c Scintigraphy with labeled
leucocytes showing normal
ﬁndings, on this data we decided
to stop the therapy
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